We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Reneo Pharmaceuticals Inc | NASDAQ:RPHM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 1.25 | 1.54 | 1.52 | 1.48 | 1.48 | 74,951 | 01:00:00 |
From Jul 2023 to Jul 2024
Jefferies Biotech CNS/Neuro SummitDate: Wednesday, October 11, 2023 Location: Jefferies Conference Center, New York, NY
About Reneo PharmaceuticalsReneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com
Matthew Purcell, Pharm.D.Media Inquiries Russo Partners, LLC matthew.purcell@russopartnersllc.com
1 Year Reneo Pharmaceuticals Chart |
1 Month Reneo Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
